Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Minimally invasive bipolar ablation system shows promise for treating atrial fibrillation

AtriCure : 08 January, 2008  (New Product)
AtriCure has announced positive results from a thoracic surgery study using the company’s minimally invasive bipolar ablation system help to treat atrial fibrillation (AF).
Dr James H Wudel, a prominent cardiac surgeon, and colleagues from the Nebraska Heart Hospital, Lincoln, Nebraska, published the results in The Annals of Thoracic Surgery.

Dr Wudel reported the results from 22 patients with symptomatic, drug refractory, intermittent AF who underwent a video assisted, minimally invasive, thoracoscopic pulmonary vein isolation procedure using the AtriCure minimally invasive bipolar ablation system. Additionally, in 21 of the 22 patients, the left atrial appendage was removed.

Of the 22 symptomatic, drug refractory, intermittent AF patients, eight patients presented with persistent AF and 14 patients presented with paroxysmal AF. All 22 patients were followed for a minimum of one year with an average follow-up of eighteen months. Holter monitoring was applied at the final follow-up to more accurately determine the rhythm status.

At the final follow-up, 20 patients (91 percent) were in normal sinus rhythm and off antiarrhythmic drugs. Additionally, 20 patients (91 percent) were no longer taking warfarin at the end of the study period.

Dr James H Wudel commented, 'These promising minimally invasive products and techniques provided desirable results and are a viable option for selected AF patients. On average our length of hospital stay was three days and our patients went home to an improved quality of life. We look forward to the continued development of these minimally invasive tools and the ongoing investigation of their clinical outcomes.'

'These results are consistent with previously published and presented data and further strengthen our confidence, commitment and conviction in our ability to expand the treatment options for those patients who suffer from AF and reinforce our commitment to pursuing AF approvals for our products from the Food and Drug Administration (FDA),' said David J Drachman, AtriCure's president and chief executive officer. 'During 2008 we anticipate a series of additional publications, national presentations and new products that we believe will stimulate further growth from our minimally invasive business.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo